Shares of Immuron (ASX:IMC) rose past 8% in recent Friday trade after it said late Thursday that it expects no material impact from the newly introduced US tariffs on pharmaceutical products.

In the same statement, the company said top-line results from the clinical study of IMM-124E, or Travelan, for traveler's diarrhea will be released this month, advancing toward US Food and Drug Administration (FDA) phase 3 trials.

In addition, the company said it plans to submit an application with the US FDA by mid-October to advance IMM-529 into phase 2 trials for Clostridioides difficile infection, an infection of the colon caused by the Clostridioides difficile bacteria.

The company is fast-tracking a limited launch in Australia of ProIBS for irritable bowel syndrome in the fourth quarter, with a full rollout targeted for 2026. IMM-986, developed with Monash University, starts pre-clinical studies by year-end to tackle antimicrobial resistance, the company added.